




## RICHARD PAUL RICHMAN CENTER FOR BUSINESS, LAW, AND PUBLIC POLICY

### **COVID Vaccines: Policies to end this pandemic and avoid another one**



How should the private and public sectors adapt to further the effort to vaccinate the U.S. population, produce sufficient supplies for countries that have thus far had only limited access to the vaccine, and develop booster vaccines to maintain immunity, particularly in the face of new variants?

Please join us for an interactive discussion with some of Columbia University's leading experts.

Topics for discussion will include i) new variants and the urgency of the Covid-19 vaccine campaign, ii) public and private sector investment and incentives for vaccine innovation and production, iii) global partnerships to increase vaccine capacity and improve allocation, and iv) how to maintain or improve incentives for innovation to protect against future pandemics.

The session will include open discussion and audience Q&A.

**Thursday, June 10, 2021**

**6:00-7:15 p.m. EST**

**REGISTER**

---

## Panelists

**Wafaa El-Sadr, MD, MPH, MPA** is University Professor of Epidemiology and Medicine, Director of ICAP at Columbia University, Director of Columbia World Projects and the Mathilde Krim-amfAR Professor of Global Health at the Columbia Mailman School of Public Health. Her work through ICAP in more than 30 countries around the world integrates research, education, training and program design, implementation, scale-up and evaluation. It aims to address major public health challenges through partnership, innovation and collaboration. ICAP has longstanding history of work in New York City with two community research sites in Harlem and the Bronx. The focus on the work has expanded over the years to include the breadth of health challenges around the world and most recently to addressing the COVID-19 pandemic.

Dr. El-Sadr received her medical degree from Cairo University in Egypt, a masters degree in public health (Epidemiology) from Columbia Mailman School of Public Health and a masters degree in public administration from the Harvard University Kennedy School of Government. She was named a McArthur fellow in 2008, is a member of the National Academy of Medicine in 2009 and a fellow of the African Academy of Sciences in 2018.

---

**Professor Bhaven Sampat** is an Associate Professor at the Department of Health Policy and Management at Columbia University and a Research Associate at the National Bureau of Economic Research (NBER). His research focuses on the economics and political economy of science and technology, primarily in the life sciences. His current projects examine: (1) The effects of the globalization of drug patent protection on innovation, prices, and access to medicines; (2) The impact of the World War II research effort on the rate and direction of postwar science and innovation, and on the scientists involved; (3) The role of the government in pharmaceutical innovation, and implications for public policy; and (4) The economics of crisis innovation and crisis innovation policy. His previous work includes research on the political economy of the NIH, the economic impact of public science, patent data as economic indicators, the economics of the patent system, pharmaceutical and life science patent policy, and university entrepreneurship/technology transfer.

---

**Dr. Magda Sobieszczyk** is the Harold C. Neu Professor of Infectious Diseases (in Medicine) and Chief, Division of Infectious Diseases at Columbia University Irving Medical Center in New York.

She is a clinical virologist and the principal investigator of the NIH-funded Columbia Collaborative Clinical Trials Unit which has been advancing the science of HIV and, most recently, of emerging infections like COVID-19. She leads and conducts international studies on the treatment and prevention of these infections. Her work also extends to evaluating interventions that address healthcare disparities and access to HIV and COVID care and prevention in the Black and Latino communities. Since the start of the COVID-19 pandemic, she has established and led studies that further our understanding of SARS-CoV-2 seroprevalence and include evaluation of responses to the vaccine and assessing viral and immunologic phenotypes that shape the development of post-COVID sequelae among diverse patients. At the national and local level she has also led efficacy studies of HIV vaccines, COVID-19 vaccines and novel interventions to prevent and treat COVID-19 and HIV.

---

**Professor Ashley Swanson** (Moderator) is an Assistant Professor at Columbia University's Business School. An applied microeconomist, Professor Swanson's research focuses primarily on the economics of health care. In particular, she studies the effects of industrial organization and information on choices, costs, and health outcomes. Her recent work has examined the effect of physician ownership on health care quality and provider incentives; the effects of lack of transparency and other frictions on negotiations

between hospitals and suppliers; the effects of complex prices and payments from pharmaceutical firms on prescription drug utilization and prices; and the effects of insurers' provider and pharmacy networks on prices.

**Professor Stephen P. Zeldes**, Frank R. Lautenberg Professor of Economics and Public Policy at Columbia Business School and co-director of the Richman Center, will introduce the event.

**The event will be recorded and registration is required.**